- Previous Close
1,385.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 3,235.00 - Volume
0 - Avg. Volume
2,293,229 - Market Cap (intraday)
159.208B - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 2021
- 1y Target Est
--
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.
www.humasis.comRecent News: 205470.KQ
View MorePerformance Overview: 205470.KQ
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 205470.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 205470.KQ
View MoreValuation Measures
Market Cap
159.21B
Enterprise Value
-20.77B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.51
Price/Book (mrq)
0.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-119.79%
Return on Assets (ttm)
-2.43%
Return on Equity (ttm)
-13.28%
Revenue (ttm)
25.41B
Net Income Avi to Common (ttm)
-30.49B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
194.68B
Total Debt/Equity (mrq)
5.90%
Levered Free Cash Flow (ttm)
16.93B